SCHEMBL4258180

SCHEMBL4258180

CCC(O)Oc1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.43
PPARG P37231 2/20 0.41
PPARA Q07869 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
SLC6A4 P31645 1/20 0.39
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TSHR P16473 1/20 0.37
CXCL12 P48061 1/20 0.37
HPGD P15428 1/20 0.36
FAAH O00519 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11303015 0.89 TSHR (0.46) PPARGPPARAKMT2AMAPTSMN1; SMN2
SCHEMBL8674766 0.83 MAPT (0.44) PPARGPPARAMAPTCYP1A2CYP2C19
SCHEMBL10359315 0.81 ACHE (0.41) ALDH1A1PPARGPPARANPSR1MEN1
SCHEMBL27841639 0.81 PPARG (0.42) ALDH1A1PPARGPPARANPSR1MEN1
SCHEMBL31027992 0.81 CA12 (0.48) ALDH1A1PPARGPPARAKMT2A
SCHEMBL11371209 0.81 LTA4H (0.47) TDP1MEN1KMT2AMAPTCYP1A2
SCHEMBL10359830 0.79 PPARG (0.41) ALDH1A1PPARGPPARANPSR1MEN1
SCHEMBL10359293 0.79 PPARA (0.43) PPARGPPARANPSR1SLC6A4CYP1A2
SCHEMBL31733888 0.79 TSHR (0.37) TSHR
SCHEMBL6903667 0.79 TSHR (0.37) PPARGPPARAKMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090082415-A1 Topical treatment of cataracts in dogs BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA 2009-03-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082415-A1 Topical treatment of cataracts in dogs AKR1A1, AKR1B1, AKR1C1 ALDH1A1 40/4885PPARG 59/4885PPARA 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.